Diagnostic Imaging Hospital Radiopharmaceuticals 
AuntMinnie
JULY 12, 2024
As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. Image courtesy of Washington University. "We Nuclear Regulatory Commission and is an integral part of a theranostics practice.
AuntMinnie
NOVEMBER 12, 2024
A dedicated teacher and radiologic technologist since 2009, Stewart currently serves as associate professor of diagnostic imaging, and program director of radiologic sciences at Quinnipiac University in Connecticut. We're more than 20 hospitals now," Beyder said. "I Louis, MO Dmitry Beyder. from Ukraine. from Ukraine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
JUNE 3, 2024
With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.
AuntMinnie
OCTOBER 25, 2024
His area of expertise is neuroradiology, with a special emphasis on diagnostic imaging of the head, neck, brain, and spine. Louis School of Medicine and completed his residency and a neuroradiology fellowship at Massachusetts General Hospital in Boston. He earned his medical degree from Washington University in St.
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.
Imaging Technology
APRIL 3, 2023
produced, non-uranium based Mo-99 for use in diagnostic imaging. Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit.
AuntMinnie
JUNE 20, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.
Expert insights. Personalized for you.
264 
Let's personalize your content